Ranbaxy OTC antihistamine
This article was originally published in The Tan Sheet
Executive Summary
The India-based firm receives FDA approval to manufacture and commercialize 10 mg tablets of its bioequivalent to OTC Claritin Reditabs (loratadine), Ranbaxy subsidiary Ohm Laboratories says April 12. Loratadine provided in orally disintegrating tablets has annual sales of $58.7 million, according to North Brunswick, N.J.-based Ohm, which sells and distributes generic and private-label OTC products in the U.S. Ranbaxy says the product will be distributed by Ohm and will be available in U.S. markets in late June this year. Schering-Plough filed for a Claritin switch in March 2002 and received an approval in November that year (1"The Tan Sheet" Dec. 9, 2002, p. 4)...
You may also be interested in...
Import Alert On Drugs From Ranbaxy’s Plants Includes OTC Product
India's largest drug maker, Ranbaxy, faces a hurdle to growing its U.S. business with FDA's ban on imports of some of its products, including an OTC drug
Schering OTC Claritin Coupons Appearing In Newspapers Dec. 15
Schering-Plough is offering consumers free samples of Claritin through a new Web site that became operational shortly after the drug's OTC approval
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.